Black Diamond Therapeutics filings document financial results, clinical-program disclosures and governance matters for a Nasdaq-listed clinical-stage oncology company. Recent Form 8-K reports furnish quarterly and annual operating results and corporate updates tied to silevertinib, the company’s EGFR MasterKey inhibitor program for EGFR-mutant NSCLC and glioblastoma, along with liquidity and capital-expenditure commentary.
Proxy materials disclose annual meeting matters, including board-class elections, auditor ratification, advisory executive-compensation votes and the preferred frequency of future compensation votes. The filings also identify the company’s registered common stock, par value and Nasdaq Global Select Market listing under the BDTX symbol.
Director Ali Behbahani of Black Diamond Therapeutics reported acquiring 6,170 shares of common stock at $2.33 per share on June 20, 2025. The shares were issued as compensation for annual services as a non-employee director, in lieu of cash compensation under the company's Fifth Amended and Restated Non-Employee Director Compensation Policy.
Following the transaction, Behbahani directly owns 77,150 shares and indirectly controls 4,448,757 shares through NEA 16 GP, LLC, where he serves as a manager. The indirect ownership is through a complex structure involving NEA Partners 16, L.P. and New Enterprise Associates 16, L.P., though Behbahani disclaims beneficial ownership of these shares under Section 16 rules.
This Form 4 filing demonstrates continued insider engagement through equity-based compensation, with the director choosing stock over cash compensation, potentially indicating confidence in the company's future prospects.
Black Diamond Therapeutics Director Prakash Raman acquired 5,526 shares of common stock at $2.33 per share on June 20, 2025, bringing their total direct ownership to 22,519 shares.
Key details of the transaction:
- The shares were issued under the company's Fifth Amended and Restated Non-Employee Director Compensation Policy
- The acquisition represents an election to receive stock in lieu of cash compensation for annual services as a non-employee director
- The reported price is based on the closing market price of the company's common stock on June 18, 2025
- The transaction was reported via Form 4 filing, executed by Attorney-in-Fact Brent Hatzis-Schoch